vs
Apyx Medical Corp（APYX）与iRhythm Holdings, Inc.（IRTC）财务数据对比。点击上方公司名可切换其他公司
iRhythm Holdings, Inc.的季度营收约是Apyx Medical Corp的10.9倍（$208.9M vs $19.2M）。iRhythm Holdings, Inc.净利率更高（2.7% vs -6.8%，领先9.4%）。Apyx Medical Corp同比增速更快（34.7% vs 27.1%）。iRhythm Holdings, Inc.自由现金流更多（$14.5M vs $-2.8M）。过去两年Apyx Medical Corp的营收复合增速更高（36.8% vs 25.8%）
Apyx Medical前身是博维医疗，是美国的医疗器械制造商，专注生产电外科产品与能源技术相关医疗设备，公司总部位于佛罗里达州克利尔沃特，在保加利亚设有生产工厂。
iRhythm Holdings是一家专注于心脏护理领域的数字医疗企业，开发可穿戴动态心脏监测设备及配套AI分析工具，主要服务美国市场的医疗机构与患者，帮助检测房颤等心律异常病症，为临床诊断提供可靠的数据支持。
APYX vs IRTC — 直观对比
营收规模更大
IRTC
是对方的10.9倍
$19.2M
营收增速更快
APYX
高出7.6%
27.1%
净利率更高
IRTC
高出9.4%
-6.8%
自由现金流更多
IRTC
多$17.3M
$-2.8M
两年增速更快
APYX
近两年复合增速
25.8%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $19.2M | $208.9M |
| 净利润 | $-1.3M | $5.6M |
| 毛利率 | 62.6% | 70.9% |
| 营业利润率 | 0.1% | 1.1% |
| 净利率 | -6.8% | 2.7% |
| 营收同比 | 34.7% | 27.1% |
| 净利润同比 | 71.9% | 518.5% |
| 每股收益（稀释后） | — | $0.18 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APYXIRTC
| Q4 25 | $19.2M | $208.9M | ||
| Q3 25 | $12.9M | $192.9M | ||
| Q2 25 | $11.4M | $186.7M | ||
| Q1 25 | $9.4M | $158.7M | ||
| Q4 24 | $14.2M | $164.3M | ||
| Q3 24 | $11.5M | $147.5M | ||
| Q2 24 | $12.1M | $148.0M | ||
| Q1 24 | $10.2M | $131.9M |
净利润APYXIRTC
| Q4 25 | $-1.3M | $5.6M | ||
| Q3 25 | $-2.0M | $-5.2M | ||
| Q2 25 | $-3.8M | $-14.2M | ||
| Q1 25 | $-4.2M | $-30.7M | ||
| Q4 24 | $-4.6M | $-1.3M | ||
| Q3 24 | $-4.7M | $-46.2M | ||
| Q2 24 | $-6.6M | $-20.1M | ||
| Q1 24 | $-7.6M | $-45.7M |
毛利率APYXIRTC
| Q4 25 | 62.6% | 70.9% | ||
| Q3 25 | 64.4% | 71.1% | ||
| Q2 25 | 62.3% | 71.2% | ||
| Q1 25 | 60.1% | 68.8% | ||
| Q4 24 | 63.0% | 70.0% | ||
| Q3 24 | 60.5% | 68.8% | ||
| Q2 24 | 61.7% | 69.9% | ||
| Q1 24 | 58.1% | 66.3% |
营业利润率APYXIRTC
| Q4 25 | 0.1% | 1.1% | ||
| Q3 25 | -6.5% | -4.4% | ||
| Q2 25 | -22.6% | -10.0% | ||
| Q1 25 | -32.4% | -20.5% | ||
| Q4 24 | -21.4% | -2.5% | ||
| Q3 24 | -31.6% | -34.1% | ||
| Q2 24 | -45.7% | -15.5% | ||
| Q1 24 | -64.6% | -28.9% |
净利率APYXIRTC
| Q4 25 | -6.8% | 2.7% | ||
| Q3 25 | -15.4% | -2.7% | ||
| Q2 25 | -33.2% | -7.6% | ||
| Q1 25 | -44.0% | -19.3% | ||
| Q4 24 | -32.5% | -0.8% | ||
| Q3 24 | -40.9% | -31.3% | ||
| Q2 24 | -54.0% | -13.6% | ||
| Q1 24 | -74.0% | -34.6% |
每股收益（稀释后）APYXIRTC
| Q4 25 | — | $0.18 | ||
| Q3 25 | — | $-0.16 | ||
| Q2 25 | — | $-0.44 | ||
| Q1 25 | — | $-0.97 | ||
| Q4 24 | — | $-0.03 | ||
| Q3 24 | — | $-1.48 | ||
| Q2 24 | $-0.19 | $-0.65 | ||
| Q1 24 | $-0.22 | $-1.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $31.7M | $583.8M |
| 总债务越低越好 | $37.5M | — |
| 股东权益账面价值 | $14.5M | $152.7M |
| 总资产 | $66.8M | $1.0B |
| 负债/权益比越低杠杆越低 | 2.58× | — |
8季度趋势，按日历期对齐
现金及短期投资APYXIRTC
| Q4 25 | $31.7M | $583.8M | ||
| Q3 25 | $25.1M | $565.2M | ||
| Q2 25 | $29.3M | $545.5M | ||
| Q1 25 | $31.0M | $520.6M | ||
| Q4 24 | $31.7M | $535.6M | ||
| Q3 24 | $28.0M | $522.0M | ||
| Q2 24 | $32.7M | $561.5M | ||
| Q1 24 | $37.3M | $569.1M |
总债务APYXIRTC
| Q4 25 | $37.5M | — | ||
| Q3 25 | $37.5M | — | ||
| Q2 25 | $37.5M | — | ||
| Q1 25 | $37.5M | — | ||
| Q4 24 | $37.5M | — | ||
| Q3 24 | $37.5M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益APYXIRTC
| Q4 25 | $14.5M | $152.7M | ||
| Q3 25 | $5.8M | $121.9M | ||
| Q2 25 | $7.3M | $103.7M | ||
| Q1 25 | $10.5M | $86.7M | ||
| Q4 24 | $14.2M | $90.9M | ||
| Q3 24 | $11.0M | $71.8M | ||
| Q2 24 | $14.7M | $99.2M | ||
| Q1 24 | $20.3M | $90.3M |
总资产APYXIRTC
| Q4 25 | $66.8M | $1.0B | ||
| Q3 25 | $57.4M | $995.2M | ||
| Q2 25 | $58.2M | $964.0M | ||
| Q1 25 | $60.2M | $926.1M | ||
| Q4 24 | $64.8M | $931.4M | ||
| Q3 24 | $60.7M | $909.7M | ||
| Q2 24 | $65.4M | $919.2M | ||
| Q1 24 | $70.7M | $909.8M |
负债/权益比APYXIRTC
| Q4 25 | 2.58× | — | ||
| Q3 25 | 6.41× | — | ||
| Q2 25 | 5.17× | — | ||
| Q1 25 | 3.57× | — | ||
| Q4 24 | 2.64× | — | ||
| Q3 24 | 3.40× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.5M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $-2.8M | $14.5M |
| 自由现金流率自由现金流/营收 | -14.6% | 6.9% |
| 资本支出强度资本支出/营收 | 1.4% | 5.6% |
| 现金转化率经营现金流/净利润 | — | 4.70× |
| 过去12个月自由现金流最近4个季度 | $-9.1M | $34.5M |
8季度趋势，按日历期对齐
经营现金流APYXIRTC
| Q4 25 | $-2.5M | $26.2M | ||
| Q3 25 | $-3.5M | $34.9M | ||
| Q2 25 | $-1.2M | $27.7M | ||
| Q1 25 | $-702.0K | $-7.9M | ||
| Q4 24 | $-2.9M | $19.2M | ||
| Q3 24 | $-4.4M | $24.3M | ||
| Q2 24 | $-4.3M | $11.8M | ||
| Q1 24 | $-6.3M | $-52.0M |
自由现金流APYXIRTC
| Q4 25 | $-2.8M | $14.5M | ||
| Q3 25 | $-4.1M | $20.1M | ||
| Q2 25 | $-1.5M | $17.3M | ||
| Q1 25 | $-757.0K | $-17.3M | ||
| Q4 24 | $-3.2M | $12.4M | ||
| Q3 24 | $-4.6M | $15.5M | ||
| Q2 24 | $-4.6M | $3.4M | ||
| Q1 24 | $-6.4M | $-61.8M |
自由现金流率APYXIRTC
| Q4 25 | -14.6% | 6.9% | ||
| Q3 25 | -31.5% | 10.4% | ||
| Q2 25 | -13.2% | 9.3% | ||
| Q1 25 | -8.0% | -10.9% | ||
| Q4 24 | -22.4% | 7.5% | ||
| Q3 24 | -40.0% | 10.5% | ||
| Q2 24 | -38.0% | 2.3% | ||
| Q1 24 | -62.2% | -46.8% |
资本支出强度APYXIRTC
| Q4 25 | 1.4% | 5.6% | ||
| Q3 25 | 4.0% | 7.7% | ||
| Q2 25 | 2.3% | 5.6% | ||
| Q1 25 | 0.6% | 5.9% | ||
| Q4 24 | 1.7% | 4.2% | ||
| Q3 24 | 1.3% | 6.0% | ||
| Q2 24 | 2.4% | 5.7% | ||
| Q1 24 | 0.3% | 7.4% |
现金转化率APYXIRTC
| Q4 25 | — | 4.70× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APYX
暂无分部数据
IRTC
| Commercial Payors | $111.7M | 53% |
| Centers For Medicare And Medicaid | $49.2M | 24% |
| Healthcare Institutions | $34.3M | 16% |
| Non Contracted Third Party Payors | $13.7M | 7% |
